Eli Lilly and Company (LLY) Friday said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for donanemab for the treatment of early symptomatic Alzheimer's disease.
The positive opinion was primarily based on data from the TRAILBLAZER-ALZ 2 study, which showed donanemab significantly slowed cognitive and functional decline and reduced the risk of progressing to the next stage of disease, as well as the TRAILBLAZER-ALZ 6 study evaluating a modified titration dosing schedule. Donanemab, marketed as Kisunla, is approved for the treatment of early symptomatic Alzheimer's disease in several countries including U.S, U.K, Japan, and China among others.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.